Skip to content
17 | 05 | 2024

Announcing Clinical Trial Aimed at Studying LM® LLLT and its Biochemical Regulation Effects on the Ocular Microbiome


Espansione Group is proud to announce the initiation of a prospective clinical trial, Photobiomodulation of the Ocular Surface and Eyelids (POSE): Red vs Blue Wavelengths. This groundbreaking study aims to investigate the effects of Light Modulation® Low-Level Light Therapy (LM® LLLT) using red versus blue wavelengths on eyelid hemodynamics, microbiome, and conventional ocular surface measures in patients suffering from dry eye disease. This innovative research underscores Espansione Group's commitment to pioneering in the field of light-based medical technologies and offers a new horizon in the treatment of ocular conditions.


The study will be conducted as a randomized, double-masked clinical trial to explore the differential impacts of red and blue wavelengths utilized in photobiomodulation. Participants will be selected based on specific inclusion criteria, including symptoms and signs of dry eye disease and Meibomian gland dysfunction.This research is motivated by the limited exploration into the varied effects of different light wavelengths on the ocular surface, despite the established benefits of photobiomodulation in managing chronic inflammatory conditions like dry eye disease.


Professor James S. W. Wolffsohn, a distinguished authority in ophthalmology, has expressed his enthusiasm about collaborating with Espansione and leading this study. He remarked, “We are really excited to be working with Espansione on this low-level light therapy project. We have found it to be a very effective and pleasant therapy for our dry eye patients. This research will allow the mechanism of the benefits to be better understood to further enhance patient treatment.


Matteo Corbellino, Executive Board Member and Chief Marketing & Innovation Officer at Espansione Group, also shared his excitement, stating: “We’re thrilled to collaborate with Aston University and Prof. J. Wolffsohn’s team. With this effort we’re really pushing the envelope in ophthalmology research, deepeing our understanding of the impact of our disruptive LM® LLLT technology.”


Espansione Group's commitment to advancing ophthalmic care through innovative research is further highlighted by the inclusion of Espansione’s proprietary technologies, the eye-light® system, which incorporates LM® LLLT, their patented photobiomodulation technology, providing a disruptive approach to treating ocular surface conditions.



Professor James Wolffsohn is an esteemed academic and researcher in the field of ophthalmology with an extensive research portfolio, positioning him as a foremost expert in his field. Since 2000, Prof. Wolffsohn is an esteemed Professor of Optometry at Aston University, located in the heart of Birmingham, UK, a leading institution known for its world-class teaching and research in a diverse array of fields.

Before taking on his current position, Prof. Wolffsohn contributed his expertise as the Deputy Executive Dean for Life and Health Sciences and served as an associate Pro-Vice Chancellor. He embarked on his illustrious career as a Clinical Research Fellow at the University of Melbourne, Australia. Prof. Wolffsohn's research primarily focuses on advancing ophthalmic instrumentation, the development and assessment of contact lenses and intraocular lenses, and exploring the complexities of the tear film.

Recognized as a National Teaching Fellow, he has authored over 280 peer-reviewed publications and is a prominent figure at international conferences. Prof. Wolffsohn plays a vital role in the optometry community as the academic Chair of the British Contact Lens Association, having served as its past president. He also contributed significantly as a harmonizer and sub-committee chair for the Tear Film & Ocular Surface Society's DEWS II report and chaired the BCLA Contact Lens Evidence-based Academic Reports (CLEAR). His current position as the Chief Scientific Officer for the International Myopia Institute, where he was joint-Chair of their white papers, underscores his pivotal contribution to myopia research and education.



Espansione Group is an established player in the MedTech industry. Since 1981, Espansione Group has delivered the highest standard in the industry. Every day, the company invests heavily in researching and developing the Espansione Ecosystem to achieve its ambition: establishing new paradigms in ophthalmology and beyond, driven by its desire to provide its partners and their patients with the best, certified medical technologies, Light Modulation® Low-level Light Therapy (LM® LLLT) and Optimal Power Energy® Intense Pulsed Light (OPE® IPL). Present in over 50 countries, Espansione Group's aims to continue its strong growth in years to come, relentlessly focusing its efforts on research, development, and customer excellence.       
For more information, see 

Media Contacts: 

Espansione Group   
Press Office 
© 2024 Espansione Group, All Rights Reserved   
Posted on May 17th, 2024, in Newsroom 


Get Started Now
Get in touch to find out how you can benefit from the Espansione Ecosystem of Technologies and Solutions.

In compliance with current regulations, let us know which audience you belong to:

You must fill in the form to download the file.

I want to be updated about Espansione products and services

This field is required.
This field is required.
This field is required.
A valid email address is required.
This field is required.
This field is required.
I have read the privacy policy and the terms and conditions of the site
This field is required.
I want to be updated about Espansione products and services. You can unsubscribe at any time, by using the “unsubscribe” feature at the bottom of any communication you receive.

Thank you for contacting us.